Figure 7. Pre- and postvaccination CTL responses against autologous melanoma.

Autologous melanoma cell lines, as well as autologous skin fibroblast cell lines, were established from tissue samples collected from 2 subjects vaccinated in each of the 3 study arms. These cell lines were then used as targets in a europium release lytic assay to assess CTL activity of autologous T cells collected on the day of the first vaccination (i.e., baseline) and approximately 1 month after the final vaccine dose (pre and post, respectively). Percent specific lytic activity is expressed for both autologous fibroblasts (negative control) and autologous melanoma cells. E:T, effector/target ratio. Data represent mean ± SEM of triplicate measurements.